Thyroid Lobectomy for Thyroid Cancer

This trial explores a new surgical approach, Thyroid Lobectomy with Ipsilateral Central Neck Dissection, to treat medullary thyroid cancer (MTC) without a RET genetic mutation. Instead of removing the entire thyroid gland, the trial tests removing only the affected part and nearby tissues. This method might lower the risk of complications and reduce the need for lifelong hormone therapy. It could be suitable for individuals diagnosed with MTC who lack the RET mutation and require surgery. As an unphased trial, it offers a unique opportunity to explore innovative surgical techniques that could potentially improve patient outcomes.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that thyroid lobectomy with removal of nearby neck tissue is generally well-tolerated. Similar surgeries, such as preventive neck tissue removal, carry known risks, including nerve damage, low calcium levels due to issues with nearby glands, and bleeding. These risks are also common in more extensive surgeries, like total thyroid removal.

Thyroid lobectomy involves removing only the affected part of the thyroid and some nearby tissue, making it less extensive than removing the entire thyroid. Studies comparing lobectomy with more extensive surgeries suggest that lobectomy may lead to fewer complications and a quicker recovery. For instance, one study found that patients who underwent a lobectomy experienced fewer problems than those who had their entire thyroid removed.

Unlike the standard of care for thyroid cancer, which often involves a total thyroidectomy, this treatment focuses on a thyroid lobectomy with ipsilateral central neck dissection. This approach aims to preserve more of the thyroid gland, potentially reducing the need for lifelong thyroid hormone replacement therapy. Researchers are excited about this method because it could offer a less invasive option with fewer long-term side effects, while still effectively monitoring and treating any residual disease with follow-up imaging and blood tests. This approach not only targets cancer effectively but also emphasizes patient quality of life by minimizing unnecessary surgical interventions.

Research has shown that a thyroid lobectomy with removal of nearby lymph nodes, which participants in this trial will undergo, can effectively treat some thyroid cancers. Studies have found that this method can lead to survival and recurrence rates similar to those of more extensive surgeries, such as removing the entire thyroid. For example, one study found that this approach resulted in excellent survival and low recurrence rates in patients with low-risk papillary thyroid cancer. This suggests it might also work well for similar conditions, like sporadic medullary thyroid cancer (MTC). Additionally, this surgery might lower the risk of complications and reduce the need for lifelong hormone replacement therapy, often necessary after removing the entire thyroid. This could improve patients' quality of life without increasing the risk of cancer recurrence.¹²⁶⁷⁸